These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 25864651

  • 1. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway.
    Zheng YT, Yang HY, Li T, Zhao B, Shao TF, Xiang XQ, Cai WM.
    Acta Pharmacol Sin; 2015 May; 36(5):614-26. PubMed ID: 25864651
    [Abstract] [Full Text] [Related]

  • 2. Ginsenoside Rg3 enhances the anti-proliferative activity of erlotinib in pancreatic cancer cell lines by downregulation of EGFR/PI3K/Akt signaling pathway.
    Jiang J, Yuan Z, Sun Y, Bu Y, Li W, Fei Z.
    Biomed Pharmacother; 2017 Dec; 96():619-625. PubMed ID: 29035827
    [Abstract] [Full Text] [Related]

  • 3. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH, Xue A, Julovi SM, Pavlakis N, Samra JS, Hugh TJ, Gill AJ, Peters L, Baxter RC, Smith RC.
    Clin Cancer Res; 2014 Aug 01; 20(15):4047-58. PubMed ID: 24895459
    [Abstract] [Full Text] [Related]

  • 4. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
    Wang F, Li H, Yan XG, Zhou ZW, Yi ZG, He ZX, Pan ST, Yang YX, Wang ZZ, Zhang X, Yang T, Qiu JX, Zhou SF.
    Drug Des Devel Ther; 2015 Aug 01; 9():575-601. PubMed ID: 25632225
    [Abstract] [Full Text] [Related]

  • 5. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
    Wong MH, Xue A, Baxter RC, Pavlakis N, Smith RC.
    Neoplasia; 2016 Jul 01; 18(7):425-35. PubMed ID: 27435925
    [Abstract] [Full Text] [Related]

  • 6. Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor.
    Zhang Z, Guo Y, Chen M, Chen F, Liu B, Shen C.
    Inflammopharmacology; 2021 Oct 01; 29(5):1587-1601. PubMed ID: 34322786
    [Abstract] [Full Text] [Related]

  • 7. Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/FoxO3a signalling in experimental colon cancer.
    Qazi AK, Hussain A, Khan S, Aga MA, Behl A, Ali S, Singh SK, Taneja SC, Shah BA, Saxena AK, Mondhe DM, Hamid A.
    Cancer Lett; 2015 Apr 01; 359(1):47-56. PubMed ID: 25554016
    [Abstract] [Full Text] [Related]

  • 8. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

  • 9. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.
    Lange F, Rateitschak K, Kossow C, Wolkenhauer O, Jaster R.
    World J Gastroenterol; 2012 Nov 21; 18(43):6226-34. PubMed ID: 23180942
    [Abstract] [Full Text] [Related]

  • 10. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
    Sui H, Shi C, Yan Z, Li H.
    Drug Des Devel Ther; 2015 Nov 21; 9():3183-90. PubMed ID: 26124641
    [Abstract] [Full Text] [Related]

  • 11. Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K/Akt/mTOR-mediated pathway in human pancreatic cancer cells.
    Wang F, Wang Q, Zhou ZW, Yu SN, Pan ST, He ZX, Zhang X, Wang D, Yang YX, Yang T, Sun T, Li M, Qiu JX, Zhou SF.
    Drug Des Devel Ther; 2015 Nov 21; 9():537-60. PubMed ID: 25632222
    [Abstract] [Full Text] [Related]

  • 12. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
    Nagaraju GP, Mezina A, Shaib WL, Landry J, El-Rayes BF.
    Eur J Cancer; 2016 Jan 21; 52():109-19. PubMed ID: 26682870
    [Abstract] [Full Text] [Related]

  • 13. PANC-1 pancreatic cancer cell growth inhibited by cucurmosin alone and in combination with an epidermal growth factor receptor-targeted drug.
    Wang C, Yang A, Zhang B, Yin Q, Huang H, Chen M, Xie J.
    Pancreas; 2014 Mar 21; 43(2):291-7. PubMed ID: 24518510
    [Abstract] [Full Text] [Related]

  • 14. Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells.
    Ryu YL, Jung KH, Son MK, Yan HH, Kim SJ, Shin S, Hong S, Hong SS.
    Cancer Lett; 2014 Oct 10; 353(1):68-77. PubMed ID: 25016056
    [Abstract] [Full Text] [Related]

  • 15. Cucurmosin induces apoptosis of BxPC-3 human pancreatic cancer cells via inactivation of the EGFR signaling pathway.
    Zhang B, Huang H, Xie J, Xu C, Chen M, Wang C, Yang A, Yin Q.
    Oncol Rep; 2012 Mar 10; 27(3):891-7. PubMed ID: 22139427
    [Abstract] [Full Text] [Related]

  • 16. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.
    Frolov A, Schuller K, Tzeng CW, Cannon EE, Ku BC, Howard JH, Vickers SM, Heslin MJ, Buchsbaum DJ, Arnoletti JP.
    Cancer Biol Ther; 2007 Apr 10; 6(4):548-54. PubMed ID: 17457047
    [Abstract] [Full Text] [Related]

  • 17. Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line.
    Ayub A, Yip WK, Seow HF.
    Biomed Pharmacother; 2015 Oct 10; 75():40-50. PubMed ID: 26463630
    [Abstract] [Full Text] [Related]

  • 18. Metformin and erlotinib synergize to inhibit basal breast cancer.
    Lau YK, Du X, Rayannavar V, Hopkins B, Shaw J, Bessler E, Thomas T, Pires MM, Keniry M, Parsons RE, Cremers S, Szabolcs M, Maurer MA.
    Oncotarget; 2014 Nov 15; 5(21):10503-17. PubMed ID: 25361177
    [Abstract] [Full Text] [Related]

  • 19. PDK1 is a potential therapeutic target against angiosarcoma cells.
    Wada M, Horinaka M, Yasuda S, Masuzawa M, Sakai T, Katoh N.
    J Dermatol Sci; 2015 Apr 15; 78(1):44-50. PubMed ID: 25726712
    [Abstract] [Full Text] [Related]

  • 20. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
    Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW, Griffin G.
    Mol Cancer Ther; 2006 Nov 15; 5(11):2676-84. PubMed ID: 17121914
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.